K Kian Ang

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN)
    K Kian Ang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5783-92. 2012
  2. ncbi Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma
    Kie Kian Ang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Semin Radiat Oncol 22:128-42. 2012
  3. ncbi Larynx preservation clinical trial design: summary of key recommendations of a consensus panel
    K Kian Ang
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 15:25-9. 2010
  4. ncbi Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes
    K Kian Ang
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0097, Houston, Texas 77030, USA
    Oncologist 13:899-910. 2008
  5. ncbi Prospective imaging assessment of mortality risk after head-and-neck radiotherapy
    Benjamin J Moeller
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 78:667-74. 2010
  6. ncbi Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck
    Anne S Tsao
    Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4163-9. 2006
  7. ncbi Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed
    Oliver Riesterer
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Radiother Oncol 92:383-7. 2009
  8. ncbi Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1351-5. 2008
  9. ncbi Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy
    Adam S Garden
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 85:941-7. 2013
  10. ncbi Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy
    David L Schwartz
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 78:1356-65. 2010

Detail Information

Publications85

  1. ncbi Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN)
    K Kian Ang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5783-92. 2012
    ....
  2. ncbi Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma
    Kie Kian Ang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Semin Radiat Oncol 22:128-42. 2012
    ....
  3. ncbi Larynx preservation clinical trial design: summary of key recommendations of a consensus panel
    K Kian Ang
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 15:25-9. 2010
    ..With consistent methodologies, clinical trials can more effectively evaluate and quantify the therapeutic benefit of novel treatment options for patients with locally advanced laryngeal and hypopharyngeal cancer...
  4. ncbi Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes
    K Kian Ang
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0097, Houston, Texas 77030, USA
    Oncologist 13:899-910. 2008
    ..Ideally, multidisciplinary teams weigh all these factors when making individual treatment decisions. Data from current trials will help further optimize multimodality treatment for LA-SCCHN...
  5. ncbi Prospective imaging assessment of mortality risk after head-and-neck radiotherapy
    Benjamin J Moeller
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 78:667-74. 2010
    ..Unresolved questions include whether functional or anatomic imaging might improve mortality risk assessment for this disease. We addressed these issues in a prospective institutional trial...
  6. ncbi Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck
    Anne S Tsao
    Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4163-9. 2006
    ..Phase III trials are needed to assess the contribution of concomitant boost fractionation to chemoradiotherapy...
  7. ncbi Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed
    Oliver Riesterer
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Radiother Oncol 92:383-7. 2009
    ..The present study assessed mechanisms underlying the observed improvement in C225 efficacy in pre-irradiated tissue (tumor bed)...
  8. ncbi Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1351-5. 2008
    ..This article reports the long-term toxicity, relapse patterns, and survival in patients with advanced head and neck carcinoma...
  9. ncbi Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy
    Adam S Garden
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 85:941-7. 2013
    ..To report mature results of a large cohort of patients diagnosed with squamous cell carcinoma of the oropharynx who were treated with intensity modulated radiation therapy (IMRT)...
  10. ncbi Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy
    David L Schwartz
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 78:1356-65. 2010
    ..To investigate long-term swallowing function in oropharyngeal cancer patients treated with intensity-modulated radiotherapy (IMRT), and to identify novel dose-limiting criteria predictive for dysphagia...
  11. ncbi Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy
    Lifei Zhang
    Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 64:1559-69. 2006
    ..CONCLUSIONS: We found variability in setup corrections for different regions of head-and-neck anatomy. These relative positional variations should be considered when making setup corrections or designing treatment margins...
  12. ncbi Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?
    Matthew T Ballo
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Head Neck 27:718-21. 2005
    ..Completion cervical lymphadenectomy is usually performed after excisional biopsy of nodal metastases from melanoma. Radiation (XRT) might be effective for some patients in lieu of formal lymph node dissection...
  13. ncbi Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma
    Juliette Thariat
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 82:e367-74. 2012
    ....
  14. ncbi Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure
    Steven J Frank
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 78:1005-10. 2010
    ....
  15. ncbi Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study
    Juliette Thariat
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:2698-709. 2008
    ..Its poorer prognosis compared with common SCC remains controversial. The authors investigated the outcomes of patients with BSCC who received radiotherapy and compared them with the outcomes of patients with SCC...
  16. ncbi Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma
    Adam S Garden
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:438-44. 2007
    ....
  17. ncbi IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes
    Erik P Sulman
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 73:399-409. 2009
    ..Limited data are available regarding the use of intensity-modulated radiotherapy (IMRT) for this indication. We reviewed our initial experience using IMRT for previously irradiated head and neck cancer patients...
  18. ncbi The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 72:1355-61. 2008
    ....
  19. ncbi Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225
    Nancy Lee
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10021, USA
    J Clin Oncol 27:3684-90. 2009
    ..To investigate the feasibility of intensity-modulated radiation therapy (IMRT) with or without chemotherapy, and to assess toxicities, failure patterns, and survivals in patients with nasopharyngeal carcinoma (NPC)...
  20. ncbi Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer
    David I Rosenthal
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 77:455-61. 2010
    ..To investigate the dosimetry and feasibility of carotid-sparing intensity-modulated radiotherapy (IMRT) for early glottic cancer and to report preliminary clinical experience...
  21. ncbi Sensitization of breast cancer cells to radiation by trastuzumab
    Ke Liang
    Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 2:1113-20. 2003
    ..Our results indicate that the PI3-K pathway might be the major pathway for trastuzumab-mediated radiosensitization of breast cancer cells...
  22. ncbi Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers
    Oliver Riesterer
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson, Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 79:1179-87. 2011
    ..Therefore we investigated the potency of monoclonal anti-IGF-1R antibody, A12, to enhance radiation response in upper respiratory tract cancers...
  23. ncbi DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy
    Benjamin J Moeller
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:2035-43. 2011
    ..We examined whether differential expression of double-strand DNA break (DSB) repair proteins in HNSCC, the chief mediators of DNA repair following irradiation, predict for treatment outcomes...
  24. ncbi Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 101:2567-73. 2004
    ..The authors reviewed their institutional experience to determine whether sinonasal neuroendocrine tumors of different histologies have distinct clinical characteristics that warrant individualized treatment approaches...
  25. ncbi Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22)
    Avraham Eisbruch
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
    Int J Radiat Oncol Biol Phys 76:1333-8. 2010
    ..To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer...
  26. ncbi The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group
    Prakash Chinnaiyan
    Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, USA
    Radiat Oncol 3:32. 2008
    ....
  27. ncbi Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 72:747-55. 2008
    ..This study estimates the doses and toxicities to nontarget structures during IMRT...
  28. ncbi A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma
    Faye M Johnson
    Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 63:717-24. 2005
    ..Local recurrence remains the major reason for treatment failure in advanced T-stage NPC, especially WHO types 1 and 2. Other strategies to improve local control in these patients should be investigated...
  29. ncbi The effect of dental artifacts, contrast media, and experience on interobserver contouring variations in head and neck anatomy
    David I Rosenthal
    Department of Radiation Physics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 30:191-8. 2007
    ..To investigate interobserver variability in the delineation of head-and-neck (H&N) anatomic structures on CT images, including the effects of image artifacts and observer experience...
  30. ncbi Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1171-8. 2004
    ....
  31. ncbi Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes
    Smith Apisarnthanarax
    Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 64:678-83. 2006
    ....
  32. ncbi Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation
    Xin Huang
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94025, USA
    Mol Cell 35:856-67. 2009
    ..Taken together, these data implicate an important role for mir-210 in regulating the hypoxic response of tumor cells and tumor growth...
  33. ncbi Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:4727-32. 2009
    ....
  34. ncbi MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation
    Li Wang
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Invest New Drugs 30:2113-20. 2012
    ..This long period of PARP inhibition potentially adds to the flexibility of design of future clinical trials. Thus, MK-4827 shows high potential to improve the efficacy of radiotherapy...
  35. ncbi Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment
    Ian J Bristol
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:719-30. 2007
    ..To determine the effects of three changes in radiotherapy technique on the outcomes for patients irradiated postoperatively for maxillary sinus cancer...
  36. ncbi AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo
    Mylin A Torres
    Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
    Invest New Drugs 29:554-61. 2011
    ..The present study investigated the effect of AC480, a small molecule pan-HER tyrosine kinase inhibitor, on in vitro radiosensitivity and in vivo radioresponse of a human head and neck squamous cell carcinoma cell line...
  37. ncbi Outcomes after radiotherapy for squamous cell carcinoma of the eyelid
    Janjira Petsuksiri
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:111-8. 2008
    ..Squamous cell carcinoma (SCC) of the eyelid is a rare malignancy with metastatic potential. In the current study, the outcomes of patients with SCC of the eyelid were evaluated after definitive and postoperative radiation therapy...
  38. ncbi Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer
    Juliette Thariat
    Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:974-84. 2007
  39. ncbi Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer
    Benjamin J Moeller
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
    J Clin Oncol 27:2509-15. 2009
    ..We conducted a prospective trial to identify patient populations likely to benefit from the addition of functional imaging to the assessment of radiotherapy response...
  40. ncbi Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy
    Grace L Smith
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:5119-25. 2008
    ..Cerebrovascular disease is common in head and neck cancer patients, but it is unknown whether radiotherapy increases the cerebrovascular disease risk in this population...
  41. ncbi Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system
    Jerry L Barker
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:960-70. 2004
    ..In theory, such a strategy would maximize the therapeutic ratio of RT...
  42. ncbi Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005
    ..To the authors' knowledge there are few data that correlate the expression of the epidermal growth factor receptor (EGFR) with the outcome of patients who have breast carcinoma and are treated with anthracycline chemotherapy...
  43. ncbi Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation
    Luka Milas
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 67:568-72. 2007
    ..We investigated whether additional therapeutic benefit could be achieved by continuing maintenance treatment with C225 after the completion of fractionated radiotherapy...
  44. ncbi Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck
    Naomi R Schechter
    Division of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Nucl Med 45:1683-7. 2004
    ..This study assessed the radiation dosimetry of 99mTc-labeled ethylene dicysteine (EC) C225 (EC-C225), a promising radioligand for functional tumor imaging...
  45. ncbi Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication
    Shyh Kuan Tai
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5554-7. 2004
    ....
  46. ncbi Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030-4009, USA
    Semin Radiat Oncol 14:153-66. 2004
    ..These initiatives will likely lead to improvement in the therapeutic index for patients with HNSCC...
  47. ncbi Radiation therapy for early-stage carcinoma of the oropharynx
    Ugur Selek
    Department of Radiation Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, 77030, USA
    Int J Radiat Oncol Biol Phys 59:743-51. 2004
    ..The development of second primary tumors of the UADT adversely impacts survival in these patients to as great a degree as the index cancer...
  48. ncbi Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03
    Quynh Thu Le
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305 5847, USA
    J Clin Oncol 27:4281-6. 2009
    ..To validate lysyl oxidase (LOX), a hypoxia-related protein, as a marker for metastasis in an independent head and neck cancer (HNC) patient group enrolled onto a prospective trial...
  49. ncbi TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:290-300. 2012
    ..In this study, we use a classification of TP53 mutation (disruptive vs. nondisruptive) and examine impact on clinical outcomes and radiation sensitivity...
  50. ncbi Potential role of growth factors in diminishing radiation therapy neural tissue injury
    Nicolaus H Andratschke
    Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Semin Oncol 32:S67-70. 2005
    ..Additional investigation is required to define potentially clinically useful growth factor regimens in the clinic...
  51. ncbi Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer
    Sue S Yom
    Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:469-76. 2006
    ..Despite its use in more challenging cases, CTT provides similar long-term clinical outcomes compared with standard 3FT, when computerized three-dimensional dosimetry is used to assure adequate dosimetry throughout the treated volume...
  52. ncbi Receptor signaling as a regulatory mechanism of DNA repair
    Raymond E Meyn
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Radiother Oncol 92:316-22. 2009
    ..The purpose of this review is to highlight what is currently known regarding EGFR signaling and the processes responsible for repairing radiation-induced DNA lesions that would explain the radiosensitizing effects of EGFR antagonists...
  53. ncbi Importance of patient examination to clinical quality assurance in head and neck radiation oncology
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Head Neck 28:967-73. 2006
    ..We determined the value of clinical peer review in radiation therapy for head and neck cancer that involved head and neck examination...
  54. ncbi Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer
    Lauren Averett Byers
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 9:1755-63. 2010
    ..In conclusion, serum CAF profiling, particularly in HPV-negative patients, may be useful for identifying those at highest risk for recurrence...
  55. ncbi Long-term radiotherapy outcomes for nasal cavity and septal cancers
    Matthew W Allen
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:401-6. 2008
    ..Carcinoma of the nasal cavity and septum has historically been associated with a poor prognosis. This report updates the long-term outcomes for radiotherapy (RT) of this disease site at the University of Texas M.D. Anderson Cancer Center...
  56. ncbi Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment
    David L Schwartz
    Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 74:1083-91. 2009
    ..To review institutional outcomes for patients treated for differentiated thyroid cancer with postoperative conformal external beam radiotherapy (EBRT)...
  57. ncbi Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century
    Adam S Garden
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Radiat Oncol 8:21. 2013
    ..We performed this study to assess outcomes of patients with oropharyngeal cancer treated with modern therapy approaches...
  58. ncbi Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer
    Joshua A Asper
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1950-7. 2006
    ..CONCLUSIONS: The modifications established in the 6th edition of the AJCC tumor staging system for oropharyngeal tumors appear to be useful to distinguish prognostic groups for both LC and OS based on tumor stage...
  59. ncbi Target coverage for head and neck cancers treated with IMRT: review of clinical experiences
    Adam S Garden
    Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 14:103-9. 2004
    ..This review will focus on how IMRT is being implemented into the treatment of head and neck cancer, specifically with regards to target definition and dosing issues...
  60. ncbi miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue
    Latha Ramdas
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Head Neck 31:642-54. 2009
    ....
  61. ncbi Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation
    Uma Giri
    Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 64:670-7. 2006
    ..These patients would be ideal candidates for testing systemic therapy...
  62. ncbi Combination of radiotherapy with EGFR antagonists for head and neck carcinoma
    Juliette Thariat
    Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Clin Oncol 12:99-110. 2007
    ....
  63. ncbi Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice
    Satoshi Itasaka
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:870-8. 2007
    ....
  64. ncbi Combining molecular therapeutics with radiotherapy for head and neck cancer
    Oliver Riesterer
    Deparmtnet of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Surg Oncol 97:708-11. 2008
    ..Actively investigated approaches include combining anti-EGFR agents, bioreductive hypoxic cell toxins, anti-angiogenesis agents, or inhibitors of multiple signaling pathways with radiotherapy...
  65. ncbi Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Head Neck 29:923-31. 2007
    ....
  66. ncbi Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy
    He Wang
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Phys Med Biol 50:2887-905. 2005
    ..Together, these results suggest that the accelerated demons algorithm has significant potential for delineating and tracking doses in targets and critical structures during CT-guided radiotherapy...
  67. ncbi Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14
    K Kian Ang
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 97, Houston, TX 77030, USA
    J Clin Oncol 23:3008-15. 2005
    ..To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC)...
  68. ncbi Intensity-modulated radiotherapy: is xerostomia still prevalent?
    Mark S Chambers
    Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Curr Oncol Rep 7:131-6. 2005
    ....
  69. ncbi The epidermal growth factor receptor mediates radioresistance
    Ke Liang
    Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:246-54. 2003
    ..CONCLUSION: Our results demonstrate that overexpression of the EGF receptor conferred cellular resistance to ionizing radiation. The EGF receptor is thus a valid target for potential radiosensitization...
  70. ncbi New equations for matching a low neck field to oblique upper neck fields with collimator rotation in a 3-field monoisocentric setup for head-and-neck cancers
    Maria A Manske
    Department of Radiation Physics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Med Dosim 29:86-91. 2004
    ..They predict the necessary manipulations of the LAN boost field to maintain a geometrically precise matchline, as verified by 3D treatment planning software, phantom dosimetry, and actual patient setups...
  71. ncbi Radiotherapy for cancer of the head and neck: altered fractionation regimens
    Linh N Nguyen
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Lancet Oncol 3:693-701. 2002
    ..Further data is needed before the combination of altered fractionation with chemotherapy can be recommended outside of a study setting...
  72. ncbi Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy
    Ke Liang
    Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 2:353-60. 2003
    ..Our data suggest that Akt may be a potential target for enhancing the response to radiotherapy in patients with breast cancer...
  73. ncbi Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody
    Naomi R Schechter
    Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Anticancer Drugs 14:49-56. 2003
    ..5 to 4 h in tumor bearing rodents. We conclude that 99mTc-EC-C225 may be useful to assess tumor EGFR expression. This may be useful in the future for selecting patients for treatment with C225...
  74. ncbi Management of nonsinonasal neuroendocrine carcinomas of the head and neck
    Jerry L Barker
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2322-8. 2003
    ....
  75. ncbi Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy
    K Kian Ang
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 58:959-65. 2004
    ..To present an overview of the significance of erbB tyrosine kinase family members as prognostic-predictive factors and as targets of therapeutic intervention in patients with head-and-neck carcinomas (HNCs)...
  76. ncbi Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas
    Luka Milas
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 52:514-21. 2002
    ....
  77. ncbi Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma
    Khaled A Hassan
    Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:6414-7. 2002
    ..01). Our results indicate that tumors overexpressing cyclin B1 may be resistant to RT, and cyclin B1 may be an indicator of the risk of locoregional recurrence and metastasis in patients having HNSCC receiving RT...
  78. ncbi Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
    K Kian Ang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:7350-6. 2002
    ..The data suggest that EGFR IHC should be considered for selecting patients for more aggressive combined therapies or enrollment into trials targeting EGFR signaling pathways...
  79. ncbi Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 55:322-8. 2003
    ..This retrospective study updated the results of RT for patients treated at our center. The primary focus of this study was whether a policy of using hyperfractionated RT for these patients resulted in a therapeutic gain...
  80. ncbi Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes
    Radhe Mohan
    Department of Radiation Physics, Unit 94, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 61:1258-66. 2005
    ..In this paper, we report the development of one such intermediate method that takes into account anatomic changes by deforming the intensity distributions of each beam based on deformations of anatomy as seen in the beam's-eye-view...
  81. ncbi Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies
    Luka Milas
    Experimental Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 58:966-71. 2004
    ..In this article, we review preclinical studies, primarily from our laboratory, addressing the role of EGFR in tumor radioresponse and the use of C225, a human-mouse chimeric anti-EGFR monoclonal antibody, to improve the results of RT...
  82. ncbi Radiation therapy for malignant melanoma
    Matthew T Ballo
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Surg Clin North Am 83:323-42. 2003
    ....
  83. ncbi Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells
    Uma Raju
    Department of Experimental Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 63:3263-7. 2003
    ..At the molecular level, transcriptional regulation by flavopiridol may have been involved...
  84. ncbi Radiotherapy for cutaneous malignant melanoma: rationale and indications
    Matthew T Ballo
    Department of Radiation Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 18:99-107; discussion 107-10, 113-4. 2004
    ..This will be the topic of future research...
  85. ncbi The role of apoptosis in radiation oncology
    Raymond E Meyn
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Biol 85:107-15. 2009
    ..Examples are provided in each of these areas that we believe justify a reassessment of the role that apoptosis plays in radiation oncology...